Secunderabad Chronicle

Prostate Cancer Pipeline Analysis: 200+ Companies are Working to Improve the Treatment Space

 Breaking News
  • No posts were found

Prostate Cancer Pipeline Analysis: 200+ Companies are Working to Improve the Treatment Space

November 10
14:52 2022

DelveInsight’s, “Prostate Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from Prostate Cancer Pipeline Report

  • DelveInsight’s Prostate Cancer Pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Prostate Cancer.
  • Key companies dedicated to advance the Prostate cancer drug pipeline are Pfizer, Myovant Biosciences, Effector Therapeutics, Mediolanum, Merck, ESSA Pharma, Sanofi, Astellas Pharma, AstraZeneca, Bayer, Janssen research & development LLC, Bristol Myers Squibb, Eli Lilly and Company, Amgen, POINT Biopharma, Hinnova Pharmaceuticals, Sophiris Bio, Ultimovacs, Foresee Pharmaceuticals, Luye Pharma Group, Abbott, AB science, Ferring pharmaceuticals, Jiangsu HengRui Medicine, Hoffmann-La Roche, Novartis, Celgene, Endocyte, Millennium Pharmaceuticals, Medivation, Veru, Progenics Pharmaceuticals, Boehringer Ingelheim, US Biotest, Antev, Elevation oncology, Abgenix, Astellas Pharma, Orion Pharma, Clovis Oncology, Exelixis, Takeda, Novus Therapeutics, Candel Therapeutics, Ipsen, MEI Pharma, Aragon Pharmaceuticals, MedImmune,  CytRx, Tmunity Therapeutics, Inovio Pharmaceuticals, Forma Therapeutics, Luye Pharma, Health Ever Bio-Tech, Advaxis, Corcept Therapeutics and several others. 
  • Prostate Cancer Pipeline Therapies such as P PSMA 101, Autologous adipose-derived mesenchymal stem cell therapy, EPI 7386, ODM 208, MCS 8, ADXS PSA, Exicorilant, VERU-100, and others
  • The companies and academics are working to assess challenges and seek opportunities that could influence Prostate Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Prostate Cancer.

 

Request a sample and discover the recent advances in Prostate Cancer treatment @ Prostate Cancer Pipeline Report

 

Prostate Cancer Overview

The prostate is a small walnut shaped gland in the pelvis of men. It is located next to the bladder and can be examined by getting a digital rectal exam. Prostate Cancer is a form of cancer that develops in the prostate gland. It is the second-leading cause of cancer deaths for men in the U.S. About 1 in 9 men will be diagnosed with Prostate Cancer in their lifetime. This year, nearly 250,000 men will be diagnosed with Prostate Cancer. Prostate Cancer cells can spread by breaking away from a prostate tumor. They can travel through blood vessels or lymph nodes to reach other parts of the body. After spreading, cancer cells may attach to other tissues and grow to form new tumors, causing damage where they land.

 

Recent Breakthroughs in the Prostate Cancer Treatment Landscape

  • Vaccitech is currently developing ChAdOx1-MVA 5T4 vaccine (VTP-008). This vaccine will be used in combination with the immunotherapy drug called nivolumab which is an anti-PD-1 (Programmed Death protein-1) monoclonal antibody.
  • Ultimovacs has started the clinical evaluation of Novel TET Tetanus-Epitope Targeting (TET)-platform based TENDU Vaccine for the treatment of Prostate cancer.
  • In October 2020, Foresee Pharmaceuticals announced that 505(b)(2) New Drug Application (NDA) for FP-001 LMIS 50mg, or CAMCEVI 42MG, a ready-to-use 6-month depot formulation of leuprolide mesylate, has been accepted for review by the U.S. Food and Drug Administration (FDA).
  • Takeda has granted Myovant an exclusive, worldwide license (excluding Japan and certain other Asian countries). U.S Food and Drug Administration approved the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist Relugolix on December 18, 2020, for the treatment of adult patients with advanced prostate cancer.

 

Find out more about Prostate Cancer Medication @ Prostate Cancer Treatment

 

Prostate Cancer Emerging Drugs

  • Pembrolizumab: Merck & Co
  • Talazoparib: Pfizer
  • ODM-208: Orion
  • ZEN 3694: Zenith Epigenetics
  • EPI-7386: ESSA Pharma

 

DelveInsight’s Prostate Cancer Pipeline report covers around 200+ products under different phases of clinical development like-

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Learn more about the novel and emerging Prostate Cancer pipeline therapies @ Prostate Cancer Clinical Trials

 

Scope of the Prostate Cancer Pipeline Report

  • Coverage- Global
  • Prostate Cancer Pipeline Assessment by Product Type
  • Prostate Cancer Pipeline Assessment by Stage and Product Type
  • Prostate Cancer Pipeline Assessment by Route of Administration
  • Prostate Cancer Pipeline Assessment by Stage and Route of Administration
  • Prostate Cancer Pipeline Assessment by Molecule Type
  • Prostate Cancer Pipeline Assessment by Stage and Molecule Type
  • Prostate Cancer Pipeline Companies- Pfizer, Myovant Biosciences, Effector Therapeutics, Mediolanum, Merck, ESSA Pharma, Sanofi, Astellas Pharma, AstraZeneca, Bayer, Janssen research & development LLC, Bristol Myers Squibb, Eli Lilly and Company, Amgen, POINT Biopharma, Hinnova Pharmaceuticals, Sophiris Bio, Ultimovacs, Foresee Pharmaceuticals, Luye Pharma Group, Abbott, AB science, Ferring pharmaceuticals, Jiangsu HengRui Medicine, Hoffmann-La Roche, Novartis, Celgene, Endocyte, Millennium Pharmaceuticals, Medivation, Veru, Progenics Pharmaceuticals, Boehringer Ingelheim, US Biotest, Antev, Elevation oncology, Abgenix, Astellas Pharma, Orion Pharma, Clovis Oncology, Exelixis, Takeda, Novus Therapeutics, Candel Therapeutics, Ipsen, MEI Pharma, Aragon Pharmaceuticals, MedImmune,  CytRx, Tmunity Therapeutics, Inovio Pharmaceuticals, Forma Therapeutics, Luye Pharma, Health Ever Bio-Tech, Advaxis, Corcept Therapeutics and several others
  • Prostate Cancer Therapies- P PSMA 101, Autologous adipose-derived mesenchymal stem cell therapy, EPI 7386, ODM 208, MCS 8, ADXS PSA, Exicorilant, VERU-100, and others

 

Table of content

  1. Introduction
  2. Executive Summary
  3. Prostate Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Pembrolizumab: Merck & Co
  8. Mid Stage Products (Phase II)
  9. ODM-208: Orion Pharma
  10. Early Stage Products (Phase I)
  11. EPI 7386: ESSA Pharma
  12. Preclinical and Discovery Products
  13. Drug name: Company name
  14. Inactive Products
  15. Prostate Cancer Key Companies
  16. Prostate Cancer Key Products
  17. Prostate Cancer- Unmet Needs
  18. Prostate Cancer- Market Drivers and Barriers
  19. Prostate Cancer- Future Perspectives and Conclusion
  20. Prostate Cancer Analyst Views
  21. Prostate Cancer Key Companies
  22. Appendix

 

Get a holistic view of the pipeline analysis @ Prostate Cancer Drug Pipeline and Emerging Trends 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles